Belgium Merchant Account (BPC-157 Peptide)

Belgium Merchant Account for Online Pharmacies Selling BPC-157 Peptide: Regulatory Requirements Explained

If you operate an online pharmacy in Belgium selling BPC-157 peptide through an e-commerce storefront, securing a Belgium merchant account and Merchant ID requires compliance with payment processing standards and Belgium’s stringent pharmaceutical regulatory framework, harmonized with European Union (EU) regulations. BPC-157, a synthetic peptide derived from a gastric protein and promoted for healing and anti-inflammatory effects, remains unapproved as a medicinal product in the EU as of March 2025, classifying it as a high-risk product for online sales. This section outlines BPC-157’s regulatory requirements in Belgium, the pre-qualification process for a merchant account, and what e-commerce pharmacies need to prepare.

BPC-157 Peptide’s Regulatory Status in Belgium

BPC-157 (Body Protective Compound-157) is a 15-amino-acid peptide researched for its potential to accelerate tissue repair and reduce inflammation. As of March 07, 2025, BPC-157 lacks marketing authorisation from the European Medicines Agency (EMA) or the U.S. FDA, and thus is not approved by Belgium’s Federal Agency for Medicines and Health Products (Agence Fédérale des Médicaments et des Produits de Santé, FAMHP). Belgium regulates medicines under the Law of 25 March 1964 on Medicines, aligned with EU Directive 2001/83/EC. For BPC-157 to be legally marketed as a medicinal product, it must obtain an EMA marketing authorisation via the centralised procedure under Regulation (EC) No 726/2004.

The authorisation process requires:

• Marketing Authorisation: Submission of a dossier to the EMA with clinical trial data, manufacturing details, and safety profiles, typically reviewed within 210 days post-trial completion. BPC-157 remains in early research stages (mostly animal studies), with no EMA approval by 2025.
• Prescription Status: If approved, BPC-157 would likely be classified as a prescription-only medicine (POM) under Article 1 of the Law of 25 March 1964, requiring a prescription from a Belgian-registered healthcare professional due to its pharmacological claims.
• Labelling: Compliance with EU Directive 2001/83/EC and Belgium’s Royal Decree of 14 December 2006, mandating multilingual labelling (French, Dutch, or German) with dosage instructions and safety warnings (e.g., potential risks like gastrointestinal upset, though human data is limited).

Without EMA approval, BPC-157 cannot be legally sold as a medicine in Belgium. Online pharmacies may market it as a “research chemical” or “supplement,” but if intended for human therapeutic use, it falls under medicinal product rules, prohibited under Article 3 of the Law of 25 March 1964. The FAMHP and Belgian Customs Service (Administration Générale des Douanes et Accises) enforce these regulations, targeting unauthorised sales with fines or seizures.

Pre-Qualification for a Belgium Merchant Account with BPC-157 Peptide

For an e-commerce pharmacy selling BPC-157, pre-qualifying for a Belgium merchant account involves meeting financial and regulatory criteria, with significant challenges due to its unapproved status. Payment processors like PpsRX, which handle high-risk transactions, evaluate:

1. Business Legitimacy and Documentation

• Required Documents: Business registration (e.g., Crossroads Bank for Enterprises, BCE/KBO number), proof of address, and ideally a pharmacy licence from the FAMHP or a regional Order of Pharmacists (e.g., Ordre des Pharmaciens). For BPC-157, processors may request documentation justifying its sale, such as research-use disclaimers.
• Challenge: Without EMA approval, proving legitimacy is difficult, often leading to rejection unless a non-medicinal status (e.g., supplement without therapeutic claims) is clearly established.

2. High-Risk Classification

• BPC-157 sales are high-risk due to:
  
  • Lack of regulatory approval, raising legal and liability concerns if sold for human use.
  • Potential chargebacks from customers disputing efficacy or side effects (e.g., injection site reactions or unknown long-term risks).
  • E-commerce risks like fraud, card-not-present transactions, and cross-border sales within the EU or beyond.
• Processors assess transaction history, fraud prevention tools, and risk mitigation strategies to determine eligibility.

3. E-Commerce and Pharmacy Compliance

• Website Standards: The storefront must feature SSL encryption, terms of service, refund policies, and explicit disclaimers about BPC-157’s unapproved status. Therapeutic claims are prohibited under Article 86 of EU Directive 2001/83/EC, enforced by the FAMHP’s Guidelines for Online Pharmacy Sales (aligned with EU standards and the Royal Decree of 21 January 2009).
• Import Compliance: If imported from outside the EU, BPC-157 requires a Manufacturer’s/Importer’s Authorisation from the FAMHP under Article 12 of the Law of 25 March 1964. Without EMA approval, such permits are unattainable, and unauthorised imports violate EU customs regulations.

4. Merchant ID Assignment

• Upon pre-qualification, a Merchant ID is issued for payment processing. For BPC-157, strict conditions like high reserve funds or transaction limits may apply due to its elevated risk profile.

Preparing for a Merchant ID Application in Belgium

To apply for a Merchant ID through a processor like PpsRX, e-commerce pharmacies selling BPC-157 should prepare:

• Business Records: Full documentation proving legal operation in Belgium, including a BCE/KBO number and, if applicable, an FAMHP-issued pharmacy licence.
• Regulatory Rationale: Evidence supporting BPC-157’s legal status (e.g., supplement classification with no medicinal claims or research-use labeling), though this may not satisfy processors for human-targeted sales.
• Sales Data: Estimates of monthly transaction volumes, ideally from prior peptide or supplement sales, to demonstrate financial stability.
• Banking Details: A Belgian business bank account (e.g., with KBC Bank or Belfius) for fund deposits.
• E-Commerce Infrastructure: Proof of a compliant storefront with secure payment gateways and fraud prevention measures.

Processors are likely to reject applications if BPC-157 is marketed as a medicine without authorisation, as this violates Belgian and EU regulations and increases legal risks.

Unique Challenges for BPC-157 Peptide in Belgium

BPC-157’s regulatory requirements present distinct obstacles for e-commerce pharmacies:

• Unapproved Status: Without EMA approval, legal sale as a medicine is prohibited. Marketing as a supplement under Regulation (EC) No 1924/2006 avoids medicinal rules but prohibits health claims, while therapeutic use risks enforcement under the Law of 25 March 1964.
• E-Commerce Oversight: The FAMHP aligns with EU initiatives like Operation Pangea and the Falsified Medicines Directive (Directive 2011/62/EU), targeting illicit online drug sales, with increased scrutiny of unapproved peptides via the EU Safety Features system.
• Fitness Market Demand: BPC-157’s popularity in sports and recovery circles increases misuse risks, amplifying chargeback and fraud concerns for processors.

Belgium’s Broader Pharmaceutical Oversight

The FAMHP conducts post-market surveillance under the Law of 25 March 1964, monitoring adverse reactions via the EudraVigilance system and inspecting online pharmacies for compliance. Violations can lead to fines up to €200,000 or imprisonment under Article 8, alongside product seizures. The Royal Decree of 21 January 2009 mandates that online pharmacies register with the FAMHP and display the EU common logo, while the Consumer Protection Law of 6 April 2010 enforces fair trade practices, adding pressure on unapproved sales like BPC-157.

Conclusion

Securing a Belgium merchant account for an e-commerce pharmacy selling BPC-157 peptide is challenging due to its unapproved status and Belgium’s EU-aligned regulatory framework. Without EMA authorisation, BPC-157 cannot be legally marketed as a therapeutic product, necessitating careful positioning as a supplement or research chemical to avoid enforcement. Pharmacies must provide extensive documentation and a defensible sales model, though processor approval remains uncertain without regulatory clarity. For more information on navigating this process, PpsRX offers resources via its contact-back request or pre-qualification forms, available on this page.

‍